Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

NCT04560569 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV/AIDS

Interventions

DRUG: Albuvirtide
DRUG: 3BNC117 Antibody

Sponsor

Frontier Biotechnologies Inc.